GSK1437173A Group vs Placebo Group: Number of Subjects With SAEs Related to Study Participation or to a Concurrent GSK Medication/Vaccine

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measure	Value	95% interval, lower	95% interval, upper	Method	Source
Risk in group 1	0.00559	0.00415	0.00752	wilson	ClinicalTrials.gov
Risk in group 2	0.00324	0.0022	0.00478	wilson	ClinicalTrials.gov
Risk difference, group 1 minus group 2	0.00235	0.000239	0.00454	newcombe hybrid score	ClinicalTrials.gov
Risk ratio, group 1 over group 2	1.72	1.05	2.82	log	ClinicalTrials.gov
Odds ratio, group 1 over group 2	1.73	1.05	2.83	log	ClinicalTrials.gov
Number needed to treat, for one more participant with the outcome on GSK1437173A Group than on Placebo Group	426	220	4,180	from the risk difference interval	ClinicalTrials.gov

Groups 2

Group 2 names the comparator: placebo.

Group	Title	Description	With the outcome	Analysed	ClinicalTrials.gov code	Source
Group 1	GSK1437173A Group	Subjects received herpes zoster subunit vaccine (gE/AS01B vaccine: GSK1437173A) according to a 0, 2-month schedule.	43	7,695	OG000	ClinicalTrials.gov
Group 2	Placebo Group	Subjects received saline solution (NaCl solution) as control according to a 0, 2-month schedule.	25	7,710	OG001	ClinicalTrials.gov

Outcome 5

Field	Value	Source
Type	SECONDARY	ClinicalTrials.gov
Title	Number of Subjects With SAEs Related to Study Participation or to a Concurrent GSK Medication/Vaccine	ClinicalTrials.gov
Description	The number of subjects with SAEs related to study participation or to a concurrent GSK medication/vaccine were tabulated	ClinicalTrials.gov
Time frame	During the entire study period (3 to 5 year period following Day 0)	ClinicalTrials.gov
Population	The analysis was based on TVC, which included all subjects with at least one dose of the study vaccine or place administered.	ClinicalTrials.gov

Trial 8

Field	Value	Source
Title	Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older	ClinicalTrials.gov
NCT number	NCT01165177	ClinicalTrials.gov
Phases	PHASE3	ClinicalTrials.gov
Conditions	Herpes Zoster	ClinicalTrials.gov
Interventions	Herpes Zoster Vaccine GSK1437173A, Placebo	ClinicalTrials.gov
Lead sponsor	GlaxoSmithKline	ClinicalTrials.gov
Results first posted	2017-05-01	ClinicalTrials.gov
Results on ClinicalTrials.gov	https://clinicaltrials.gov/study/NCT01165177?tab=results	ClinicalTrials.gov

Source 4

Field	Value	Source
Release	trial-comparisons-2026-03-23-0.1.0	ClinicalTrials.gov
Release manifest SHA-256	f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57	ClinicalTrials.gov
AACT copy	2026-03-23	ClinicalTrials.gov
Tables read	outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet	ClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.